Nature Communications

Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer

2026-07-27

Full text

DOI https://doi.org/10.1038/s41467-026-75960-3